References
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2022;24(1):4–131. doi: 10.1002/ejhf.2333
- Heart Failure Policy Network (HFPN). Heart failure policy and practice in Europe. London: HFPN; 2020 [cited 2023 Jul 1]. Available from: https://www.hfpolicynetwork.org/wp-content/uploads/Heart-failure-policy-and-practice-in-Europe.pdf
- Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi: 10.1002/ejhf.1858
- van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242–252. doi: 10.1002/ejhf.483
- Fonseca C, Brás D, Araújo I, et al. Heart failure in numbers: Estimates for the 21st century in Portugal. Rev Port Cardiol (Engl Ed). 2018;37(2):97–104. doi: 10.1016/j.repc.2017.11.010
- Sicras-Mainar A, Sicras-Navarro A, Palacios B, et al. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Esp Cardiol (Engl Ed). 2022;75(1):31–38. doi: 10.1016/j.recesp.2020.09.014
- Farré N, Vela E, Clèries M, et al. Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients. PloS One. 2017;12(2):e0172745. doi: 10.1371/journal.pone.0172745
- Crespo‐Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long‐Term registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–625. doi: 10.1002/ejhf.566
- Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964. doi: 10.1186/s12913-020-05828-9
- Romero T. Statista; Demographics; Number of inhabitants aged 65 or over in Spain from 2002 to 2022 (in millions) [Internet]. 2023 [cited 2023 Jul 1]. Available from: https://www.statista.com/statistics/1231682/population-of-spain-over-65-year/
- American Heart Association (AHA). Ejection fraction heart failure measurement [Internet]. 2017 [cited 2023 Jul 1]. Available from: https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement
- Aldaas OM, Igata S, Raisinghani A, et al. Accuracy of left ventricular ejection fraction determined by automated analysis of handheld echocardiograms: a comparison of experienced and novice examiners. Echocardiography. 2019;36(12):2145–2151. doi: 10.1111/echo.14546
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362(9386):777–781. doi: 10.1016/S0140-6736(03)14285-7
- Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–2345. doi: 10.1093/eurheartj/ehl250
- Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–2467. doi: 10.1056/NEJMoa0805450
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. doi: 10.1056/NEJM199909023411001
- SD S, JJ V M, IS A, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655
- CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. doi: 10.1016/S0140-6736(98)11181-9
- Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi: 10.1093/eurheartj/ehi115
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi: 10.1016/S0140-6736(99)04440-2
- Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. doi: 10.1056/NEJM200105313442201
- McDonagh TA, Metra M, Adamo M, et al. Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639. doi: 10.1093/eurheartj/ehad195
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
- Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
- European Medicines Agency (EMA). Jardiance: summary of product characteristics [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
- Food and Drug Administration (FDA). Jardiance [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf
- REvalMed-SNS. Informe De Posicionamiento Terapéutico [therapeutic positioning report] PT 112-2023/V1/21032023 Spanish [internet]. 2023 [cited 2023 Jul 1]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2023/IPT-112-2023-Jardiance-Empagliflozina.pdf
- National Institute for Health and Care Excellence (NICE). Empagliflozin for treating chronic heart failure with reduced ejection fraction [TA773] [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.nice.org.uk/guidance/ta773
- Haute Autorité de Santé (HAS). Jardiance (Insuffisance Cardiaque Chronique) (empagliflozine) [Jardiance (Chronic Heart Failure) (empagliflozin)] French [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.has-sante.fr/jcms/p_3315443/en/jardiance-icc-empagliflozine
- Haute Autorité de Santé (HAS). Jardiance (empagliflozine) - Insuffisance Cardiaque Chronique symptomatique [Jardiance (empagliflozin) - symptomatic Chronic Heart Failure] French [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.has-sante.fr/jcms/p_3352200/en/jardiance-empagliflozine-insuffisance-cardiaque-chronique-symptomatique
- Gemeinsamer Bundes-Ausschuss (G-BA). Empagliflozin (Neues Anwendungsgebiet: chronische Herzinsuffizienz) [Empagliflozin (New indication: chronic heart failure)] German [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.g-ba.de/downloads/91-1385-716/2022-01-06_GeltendeFassung_Empagliflozin_D-704.pdf
- Gemeinsamer Bundes-Ausschuss (G-BA). Empagliflozin (Neues Anwendungsgebiet: chronische Herzinsuffizienz mit linksventrikulärer Ejektionsfraktion LVEF > 40 %) [Empagliflozin (New indication: chronic heart failure with left ventricular ejection fraction LVEF > 40%)] German [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.g-ba.de/downloads/91-1385-810/2022-09-15_GeltendeFassung_Empagliflozin_D-799.pdf
- Gazzetta Ufficiale della Repubblica Italiana. Determina n.441/2023 Agenzia Italiana del Farmaco (AIFA). Serie Generale n.149 del 28 giugno 2023 [General Series n.149 of 28 June 2023] Italian [Internet]. 2023 [cited 2023 Jul 1]. Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2023-06-28&atto.codiceRedazionale=23A03669&elenco30giorni=false
- Agenzia Italiana del Farmaco (AIFA). Valutazione dell’innovativita’ medicinale Jardiance (empagliflozin) [Evaluation of the medicinal innovation Jardiance (empagliflozin)] Italian [Internet]. 2022 [cited 2023 Jul 1]. Available from: https://www.aifa.gov.it/documents/20142/1909401/18_JARDIANCE_scheda_innovativita_GRADE.pdf
- Agenzia Italiana del Farmaco (AIFA). Innovative medicines list: AIFA publishes June 2023 update [Internet]. 2023 [cited 2023 Jul 1]. Available from: https://www.aifa.gov.it/en/-/elenco-dei-farmaci-innovativi-aifa-pubblica-l-aggiornamento-di-giugno-2023
- Liao CT, Yang CT, Kuo FH, et al. Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system’s perspective in the Asia-Pacific Region. Front Cardiovasc Med. 2021;8:750381. doi: 10.3389/fcvm.2021.750381
- Zhou J, Liew D, Kaye DM, et al. Cost-effectiveness of Empagliflozin in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Qual Outcomes. 2022;15(10):e008638. doi: 10.1161/CIRCOUTCOMES.121.008638
- Tafazzoli A, Reifsnider OS, Bellanca L, et al. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction. Eur J Heal Econ. 2022;24(9):1441–1454. doi: 10.1007/s10198-022-01555-6
- Kolovos S, Bellanca L, Groyer H, et al. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%. ESC Hear Fail. 2023;10(6):3385–3397. doi: 10.1002/ehf2.14470
- Kolovos S, Bellanca L, Groyer H, et al. Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England. J Cardiovasc Med. 2023;24(10):758–764. doi: 10.2459/JCM.0000000000001532
- Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32(5):667–677. doi: 10.1177/0272989X12454577
- National Institute for Health and Care Excellence (NICE). Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [TA929] [Internet]. 2023 [cited 2023 Nov 1]. Available from: https://www.nice.org.uk/guidance/ta929
- Food and Drug Administration (FDA). Qualified medical device development tools (MDDT), Kansas City cardiomyopathy questionnaire (KCCQ) [Internet]. 2017 [cited 2023 Jul 1]. Available from: https://www.fda.gov/medical-devices/science-and-research-medical-devices/medical-device-development-tools-mddt#Qualified_Tools
- Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–1255. doi: 10.1016/S0735-1097(00)00531-3
- Zou X, Shi Q, Vandvik PO, et al. Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. Ann Intern Med. 2022;175(6):851–861. doi: 10.7326/M21-4284
- BotPlus Web Database [Internet]. 2022 [cited 2022 Mar 1]. Available from: https://botplusweb.portalfarma.com/botplus.aspx
- Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. PharmacoEcon. 2018;36(7):745–758. doi: 10.1007/s40273-018-0672-z
- Packer M, Butler J, Zannad F, et al. Empagliflozin and Major Renal Outcomes in Heart Failure. N Engl J Med. 20210827th ed 2021;385(16):1531–1533. doi: 10.1056/NEJMc2112411
- Instituto Nacional de Estadistica (INE). Calculation of variations in the consumer price index (cpi system base). 2021.
- Vallejo‐Torres L, García‐Lorenzo B, Serrano‐Aguilar P. Estimating a cost‐effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–761. doi: 10.1002/hec.3633
- Lou Y, Hu T, Huang J. Cost-effectiveness of adding empagliflozin to standard treatment for heart failure with preserved ejection fraction patients in China. Am J Cardiovasc Drugs. 2022;23(1):47–57. doi: 10.1007/s40256-022-00550-9
- Zheng J, Parizo JT, Spertus JA, et al. Cost-effectiveness of Empagliflozin in patients with heart failure with preserved ejection fraction. JAMA Intern Med. 2022;182(12):1278–1288. doi: 10.1001/jamainternmed.2022.5010
- Hossain MZ, Chew-Graham CA, Sowden E, et al. Challenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: a qualitative study of general practitioner perspectives. Chronic Illn. 2022;18(2):410–425. doi: 10.1177/1742395320983871
- Hancock HC, Close H, Fuat A, et al. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866. doi: 10.1136/bmjopen-2013-003866
- Santulli G, Varzideh F, Forzano I, et al. Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart. Hypertension. 2023;80(9):1800–1809. doi: 10.1161/HYPERTENSIONAHA.123.20598
- Forzano I, Wilson S, Lombardi A, et al. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs. 2023;32(9):839–847. doi: 10.1080/13543784.2023.2263354
- Wu E, Pellissier J, Kvamme M, et al. A holistic approach to evaluate the cost-effectiveness of Pembrolizumab with multiple indications: a Norway-based example. Value Heal. 2018;21:S7. doi: 10.1016/j.jval.2018.04.030
- Jakobsen M, Holst-Kristensen A. PDG40 the potential of a weighted average icer as a supplementary decision tool WHEN assessing the cost-effectiveness of MULTI-Indication pharmaceuticals. Value Heal. 2020;23:S526. doi: 10.1016/j.jval.2020.08.723
- Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018;138(15):1599–1601. doi: 10.1161/CIRCULATIONAHA.118.033810
- Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. doi: 10.1136/bmj-2022-074068